Sunshine Guojian Pharmaceutical(688336.SH)

Last Updated 00:00:00
longbridge loading
Company Encyclopedia
View More
name
Sunshine Guojian Pharmaceutical
688336.SH
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs. Its products include YISAIPU, a tumor necrosis factor inhibitor type II-antibody fusion protein for the treatment of autoimmune rheumatism and immunology; Septin, an injection for anti-human epidermal growth factor receptor-2 treatment; and Jiannipa, a recombinant anti-CD25 humanized monoclonal antibody injection to prevent acute rejection caused by kidney transplantation. The company was founded in 2002 and is based in Shanghai, China.
1.468 T
688336.SHMarket value -Rank by Market Cap -/-

Financial Score

19/05/2026 Update
A
BiotechnologyIndustry
Industry Ranking1/81
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE41.63%A
    • Profit Margin68.87%A
    • Gross Margin80.71%A
  • Growth ScoreA
    • Revenue YoY248.95%A
    • Net Profit YoY315.19%A
    • Total Assets YoY48.11%A
    • Net Assets YoY52.19%A
  • Cash ScoreB
    • Cash Flow Margin93.82%C
    • OCF YoY248.95%A
  • Operating ScoreB
    • Turnover0.58B
  • Debt ScoreA
    • Gearing Ratio4.11%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Innovative drug concept stocks rapidly plummeted, with NEPTUNUS hitting the daily limit, RemeGen falling more than 10%, and many stocks including Cosunter, Rundu Pharma, Sunshine Guojian Pharmaceutical, SL PHARM, and HITECK dropping more than 6%

    Wallstreetcn·
    SH
    512290
    +0.21%
    SZ
    002038
    +0.48%
    SZ
    002923
    +0.65%
    Wallstreetcn·
    SH
    512290
    +0.21%
    SZ
    002038
    +0.48%
    SZ
    002923
    +0.65%

    Pharmaceutical stocks fluctuated and surged, with Getein Biotech hitting the daily limit, RemeGen rising nearly 7%, reaching a historical high. Sunshine Guojian Pharmaceutical, EASTON BIOPHARMACEUTICALS, YKYY, Junshi Biosciences, BeBetter Med, and InventisBio also followed suit

    Wallstreetcn·
    SH
    688336
    -0.51%
    SH
    688513
    +2.21%
    HK
    01877
    -1.22%
    Wallstreetcn·
    SH
    688336
    -0.51%
    SH
    688513
    +2.21%
    HK
    01877
    -1.22%

    Sunshine Guojian Pharmaceutical: Pfizer has registered two global Phase III clinical trials for the PD-1/VEGF dual antibody PF-08634404 (SSGJ-707) on a certain website, and the final payment remains uncertain

    Zhitong·
    SH
    688336
    -0.51%
    Zhitong·
    SH
    688336
    -0.51%

    A-share innovative drug concept stocks are active again, Sunshine Guojian Pharmaceutical rose over 10% to a new high, Yatai Pharm had two consecutive limit-ups, WECOME rose over 10%, and Baicheng Pharmaceutical, ALK, and Fushine followed suit

    Zhitong·
    SZ
    300878
    -1.60%
    SZ
    300497
    -0.48%
    SZ
    002940
    +3.79%
    Zhitong·
    SZ
    300878
    -1.60%
    SZ
    300497
    -0.48%
    SZ
    002940
    +3.79%

    Midday Review: The Beijing Stock Exchange 50 Index surged over 3% in the first half of the day, with strong performance in AI application sectors such as film and media

    Zhitong·
    SH
    688336
    -0.51%
    SZ
    300071
    +1.66%
    SH
    601360
    +1.18%
    Zhitong·
    SH
    688336
    -0.51%
    SZ
    300071
    +1.66%
    SH
    601360
    +1.18%
    © 2026 Longbridge｜Disclaimer